Abstract
Aim: Felodipine (FDP), an antihypertensive drug possesses low water solubility and extensive first-pass metabolism leading to poor bioavailability. This impelled us to improve its solubility, bioavailability, and pharmacodynamic properties through the Nanocrystal (NC) approach.
Methods: FDP-NC were prepared with Poloxamer F125 (PXM) by the antisolvent precipitation method. The experimental setup aimed at fine-tuning polymer concentration, the proportion of antisolvent to solvent, and the duration of ultrasonication for NC formulation.
Results: Optimized formulation was characterized for particle size, solubility, and PDI. Particle reduction of 74.96 times was achieved with a 9X solubility enhancement as equated to pure FDP. The morphology of NC was found to be crystalline through scanning electron microscopy observation. The formation of the crystal lattice in FDP-NC was further substantiated by the XRD and DSC results. Lowering of the heat of fusion of FDP-NC is a clear indication of size reduction. The stability studies showed no substantial change in physical parameters of the FDP-NC as assessed by particle size, zeta potential, and drug content.
Conclusion: The crystalline nature and improved solubility of FDP-NC improve the dissolution profile and pharmacodynamic data. The stability study data ensure that FDP-NC can be safely stored at 25°C. It is revealed that FDP-NC had a better release profile and improved pharmacodynamic effects as evident from better control over heart rate than FDP.
Keywords: Antisolvent precipitation, cadmium chloride, felodipine, heart rate variability, heat of fusion, crystallinity.
Graphical Abstract
[http://dx.doi.org/10.4103/0973-8398.150032]
[http://dx.doi.org/10.1016/j.jconrel.2013.12.018] [PMID: 24378441]
[http://dx.doi.org/10.1016/j.ijpharm.2009.09.031] [PMID: 19781608]
[http://dx.doi.org/10.2147/IJN.S595] [PMID: 18990939]
[http://dx.doi.org/10.1038/s41598-020-60657-4] [PMID: 32107451]
[http://dx.doi.org/10.13005/bpj/1920]
[http://dx.doi.org/10.3109/03639045.2011.645830] [PMID: 22229827]
[http://dx.doi.org/10.1016/j.ejps.2013.08.030] [PMID: 23999036]
[http://dx.doi.org/10.1016/j.ijpharm.2013.01.019] [PMID: 23333709]
[http://dx.doi.org/10.1016/j.jconrel.2008.03.002] [PMID: 18423767]
[http://dx.doi.org/10.1016/j.jddst.2017.10.001]
[http://dx.doi.org/10.1016/j.jyp.2013.08.002] [PMID: 24396247]
[http://dx.doi.org/10.1007/s40005-019-00436-0]
[http://dx.doi.org/10.1007/s12247-020-09465-x]
[http://dx.doi.org/10.1007/s10847-009-9705-8]
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.060] [PMID: 24939612]
[http://dx.doi.org/10.1007/s11095-008-9791-0] [PMID: 19034626]
[http://dx.doi.org/10.1016/j.supflu.2011.07.008]
[http://dx.doi.org/10.1007/s13346-017-0453-9] [PMID: 29204927]
[http://dx.doi.org/10.1016/j.jconrel.2016.06.017] [PMID: 27297779]
[http://dx.doi.org/10.4314/tjpr.v12i2.20]
[http://dx.doi.org/10.1016/j.molliq.2018.05.129]
[http://dx.doi.org/10.2165/00003495-198500292-00005] [PMID: 3987543]
[http://dx.doi.org/10.1016/S0002-9149(96)00816-8] [PMID: 9068509]
[http://dx.doi.org/10.1038/hr.2015.30] [PMID: 25787045]